ELOX - Company ID 0001035354
The table below shows Eloxx Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.96M | $6.36M | $4.78M | $4.33M | $4.90M | $24.55M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $63.39M |
| $8.50M |
| $5.63M |
| $5.38M |
| $6.40M |
| $25.67M |
| Property, plant & equipment | - | - | $107.00K | $130.00K | $143.00K | $215.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $63.39M | $8.50M | $6.04M | $5.99M | $7.20M | $26.88M |
| Accounts payable | $3.03M | $3.03M | $3.13M | $3.12M | $2.43M | $1.59M |
| Total current liabilities | $16.97M | $16.09M | $23.47M | $21.25M | $19.46M | $21.68M |
| Long-term debt | - | - | $2.62M | $3.33M | $4.03M | $9.86M |
| Total liabilities | - | - | $26.09M | $24.59M | $23.49M | $31.86M |
| Retained earnings | -$308.84M | -$304.33M | -$288.55M | -$284.96M | -$280.62M | -$268.07M |
| Total equity | $46.42M | -$7.58M | -$20.05M | -$18.60M | -$16.29M | -$4.98M |